Abstract:Synapses represent an important target of Alzheimer disease (AD), and alterations of their excitability are among the earliest changes associated with AD development. Synaptic activation has been shown to be protective in models of AD, and deep brain stimulation (DBS), a surgical strategy that modulates neuronal activity to treat neurological and psychiatric disorders, produced positive effects in AD patients. However, the molecular mechanisms underlying the protective role(s) of brain stimulation are still elusive. We have previously demonstrated that induction of synaptic activity exerts protection in mouse models of AD and frontotemporal dementia (FTD) by enhancing the macroautophagy/autophagy flux and lysosomal degradation of pathological MAPT/Tau. We now provide evidence that TFEB (transcription factor EB), a master regulator of lysosomal biogenesis and autophagy, is a key mediator of this cellular response. In cultured primary neurons from FTD-transgenic mice, synaptic stimulation inhibits MTORC1 signaling, thus promoting nuclear translocation of TFEB, which, in turn, induces clearance of MAPT/Tau oligomers. Conversely, synaptic activation fails to promote clearance of toxic MAPT/Tau in neurons expressing constitutively active RRAG GTPases, which sequester TFEB in the cytosol, or upon TFEB depletion. Activation of TFEB is also confirmed in vivo in DBS-stimulated AD mice. We also demonstrate that DBS reduces pathological MAPT/Tau and promotes neuroprotection in Parkinson disease patients with tauopathy. Altogether our findings indicate that stimulation of synaptic activity promotes TFEB-mediated clearance of pathological MAPT/Tau. This mechanism, underlying the protective effect of DBS, provides encouraging support for the use of synaptic stimulation as a therapeutic treatment against tauopathies.Abbreviations: 3xTg-AD: triple transgenic AD mice; AD: Alzheimer disease; CSA: cyclosporine A; DBS: deep brain stimulation; DIV: days in vitro; EC: entorhinal cortex; FTD: frontotemporal dementia; gLTP: glycine-induced long-term potentiation; GPi: internal segment of the globus pallidus; PD: Parkinson disease; STN: subthalamic nucleus; TFEB: transcription factor EB.

Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

TFEB Enhances Astroglial Uptake of Extracellular Tau Species and Reduces Tau Spreading.

Stimulation of synaptic activity promotes TFEB-mediated clearance of pathological MAPT/Tau in cellular and mouse models of tauopathies

TFEB in Alzheimer's Disease: from Molecular Mechanisms to Therapeutic Implications

TFEB Regulates Lysosomal Exocytosis of Tau and Its Loss of Function Exacerbates Tau Pathology and Spreading

TFEB-vacuolar ATPase Signaling Regulates Lysosomal Function and Microglial Activation in Tauopathy.

Novel Insight into Functions of Transcription Factor EB (TFEB) in Alzheimer's Disease and Parkinson's Disease.

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

The Autophagy–Lysosomal Pathway in Neurodegeneration: A TFEB Perspective

A small molecule transcription factor EB activator ameliorates beta‐amyloid precursor protein and Tau pathology in Alzheimer's disease models

Therapeutic Potential of Vital Transcription Factors in Alzheimer’s and Parkinson’s Disease With Particular Emphasis on Transcription Factor EB Mediated Autophagy

Deacetylation of TFEB Promotes Fibrillar Aβ Degradation by Upregulating Lysosomal Biogenesis in Microglia

Transcription factor EB: an emerging drug target for neurodegenerative disorders

TFEB acetylation promotes lysosome biogenesis and ameliorates Alzheimer’s disease–relevant phenotypes in mice

Selective Degradation of Hyperphosphorylated Tau by Proteolysis-Targeting Chimeras Ameliorates Cognitive Function in Alzheimer’s Disease Model Mice

A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies

Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer's disease model mice

Overexpression of TECPR1 improved cognitive function of P301S‐tau mice via activation of autophagy in the early and late process

Intermittent hypoxia therapy ameliorates beta-amyloid pathology via TFEB-mediated autophagy in murine Alzheimer's disease

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer’s disease